Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 8, 2009

BioFocus Gains Access to DiscoveRx GPCR and cAMP Assays

  • BioFocus and DiscoveRx signed a co-marketing agreement that will allow BioFocus to carry out screening for clients using DiscoveRx' PathHunter™ ß-Arresting GPCR screening assay, HitHunter™ cAMP assays, and associated cell lines.

    The deal with BioFocus comes just days after DiscoveRx signed a global agreement with GlaxoSmithKline to provide the latter with access to its PathHunter™ ß-Arrestin parental cell lines, clones, and associated reagents for use in GSK's GPCR screening and profiling research. This agreement followed closely behind DiscoveRx and GSK's announcement of a three-way alliance with Medical Research Council Technology, focused on using the PathHunter™ ß-Arrestin assay technology to find binders to orphan GPCRs.

","DownloadsUrl":"","CompanyUrl":null,"CompanyEmail":null,"IsFavoriteItem":false,"RequestRawUrl":"/gen-news-highlights/biofocus-gains-access-to-discoverx-gpcr-and-camp-assays-br/78565155?kwrd=DiscoveRx","HasIssueInfo":false,"IssueInfo":null}; var isAuthenticated = 'False';

Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.